Amicus Therapeutics, Inc.
US ˙ NasdaqGM ˙ US03152W1099
ESTE SÍMBOLO NÃO ESTÁ MAIS ATIVO

SecurityFOLD / Amicus Therapeutics, Inc.
InstitutionQUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series
Latest Disclosed Ownership505,761 shares
Latest Disclosed Value $ 2,898,010
QUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series reports 1.14% increase in ownership of FOLD / Amicus Therapeutics, Inc.

On August 26, 2025 - QUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series filed a NPORT-P form disclosing ownership of 505,761 shares of Amicus Therapeutics, Inc. (US:FOLD) valued at $2,898,011 USD as of June 30, 2025. The entity filed a previous NPORT-P on May 28, 2025 disclosing 500,048 shares of Amicus Therapeutics, Inc.. This represents a change in shares of 1.14% during the quarter. The current value of the position is $7,328,477 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2025-08-26 2025-06-30 NP Amicus Therapeutics EC US03152W1099 505,761 5,713 1.14 2,898 -28.97 0.0651
2025-05-28 2025-03-31 NP Amicus Therapeutics EC US03152W1099 500,048 5,308 1.07 4,080 -12.45 0.0979
2025-02-25 2024-12-31 NP Amicus Therapeutics EC US03152W1099 494,740 -82,209 -14.25 4,660 -24.36 0.1018
2024-11-26 2024-09-30 NP Amicus Therapeutics EC US03152W1099 576,949 25,727 4.67 6,162 12.67 0.1165
2024-08-26 2024-06-30 NP Amicus Therapeutics EC US03152W1099 551,222 49,535 9.87 5,468 -7.46 0.1114
2024-05-28 2024-03-31 NP Amicus Therapeutics EC US03152W1099 501,687 -8,914 -1.75 5,910 -18.44 0.1233
2024-02-26 2023-12-31 NP Amicus Therapeutics EC US03152W1099 510,601 35,084 7.38 7,245 25.30 0.1546
2023-11-28 2023-09-30 NP Amicus Therapeutics EC US03152W1099 475,517 -9,831 -2.03 5,782 -5.14 0.1509
2023-08-25 2023-06-30 NP Amicus Therapeutics EC US03152W1099 485,348 43,899 9.94 6,096 24.51 0.1446
2023-05-26 2023-03-31 NP Amicus Therapeutics EC US03152W1099 441,449 6,341 1.46 4,896 -7.85 0.1304
2023-02-24 2022-12-31 NP Amicus Therapeutics EC US03152W1099 435,108 -15,846 -3.51 5,313 12.85 0.1461
2022-11-25 2022-09-30 NP Amicus Therapeutics EC US03152W1099 450,954 26,375 6.21 4,708 3.25 0.1349
2022-08-25 2022-06-30 NP Amicus Therapeutics EC US03152W1099 424,579 14,520 3.54 4,560 17.41 0.1259
2022-05-26 2022-03-31 NP Amicus Therapeutics EC US03152W1099 410,059 6,934 1.72 3,883 -16.60 0.0905
2022-02-25 2021-12-31 NP Amicus Therapeutics EC US03152W1099 403,125 -6,319 -1.54 4,656 19.08 0.1010
2021-11-24 2021-09-30 NP Amicus Therapeutics EC US03152W1099 409,444 0 0.00 3,910 -0.94 0.0861
2021-08-26 2021-06-30 NP Amicus Therapeutics EC US03152W1099 409,444 18,413 4.71 3,947 2.17 0.0847
2021-05-27 2021-03-31 NP Amicus Therapeutics EC US03152W1099 391,031 -10,125 -2.52 3,863 -58.29 0.0876
2021-02-25 2020-12-31 NP Amicus Therapeutics EC US03152W1099 401,156 -14,765 -3.55 9,263 57.73 0.2373
2020-11-25 2020-09-30 NP Amicus Therapeutics EC US03152W1099 415,921 -13,753 -3.20 5,873 -9.37 0.1885
2020-08-27 2020-06-30 NP Amicus Therapeutics EC US03152W1099 429,674 4,592 1.08 6,479 64.99 0.2118
2020-06-01 2020-03-31 NP Amicus Therapeutics EC US03152W1099 425,082 1,498 0.35 3,928 -4.80 0.1606
2020-02-27 2019-12-31 NP Amicus Therapeutics EC 03152W109 423,584 30,247 7.69 4,126 30.79 0.1241
2019-11-27 2019-09-30 NP Amicus Therapeutics EC US03152W1099 393,337 393,337 3,155 0.1043
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.